Endostatin
Trials 22
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-07-28 | Jiangsu Simcere Pharmaceutical Co., Ltd. | COSELA® and Endostar® Receive Endorsement in Chinese Medical Association's Lung Cancer Treatment Guidelines simcere.com ↗ |
| 2022-06-07 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Latest Clinical Data regarding ENDOSTAR and Trilaciclib Presented at the 2022 ASCO simcere.com ↗ |
| 2021-05-26 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Will Announce Progress of Multiple Clinical Research on Antitumor Drugs at the 2021 ASCO Annual Meeting Endostar®（Recombinant Human Endostatin Injection） Envafolimab (KNO35) simcere.com ↗ |
| 2018-04-25 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Endostar included in CSCO Guidelines on the Diagnosis and Treatment simcere.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | endostatin | “Endostar is a recombinant product of endostatin, which is an endogenous inhibitor of angiogenesis.” NCT02865304 ↗21“nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d” NCT03917069 ↗ “Endostatin ：210mg (14 doses), CIV continuously pumped for 72h, Q3W” NCT05387681 ↗ “Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib” NCT03461185 ↗ “human recombinant endostatin (endostar)” NCT01907529 ↗ |
| Known as | endostar | “Concurrently, recombinant human endostatin (Endostar) induces tumor vascular normalization and alleviates immunosuppression by inhibiting regulatory T cells (Tregs).” PMID 42291342 ↗ May 20264“human recombinant endostatin (endostar) for breast cancer patients” NCT00604435 ↗ “with or without human recombinant endostatin (endostar)” NCT01479036 ↗ “human recombinant endostatin (endostar)” NCT01907529 ↗ “recombinant human endostatin (endostar)” NCT01915134 ↗ |
| Known as | Endostatin, Simcere-Medgenn (No. S20050088) | “Endostatin, Simcere-Medgenn (No. S20050088)” NCT01479036 ↗ |
| Known as | human recombinant endostatin | “human recombinant endostatin (endostar) for breast cancer patients” NCT00604435 ↗ |
| Known as | recombinant human endostatin | “recombinant human endostatin (endostatin)” NCT05551247 ↗ |
| Known as | rh-endostatin | “To further assess the efficacy and safety of recombinant human endostatin (rh-endostatin), a Phase III, multicenter, prospective, randomized, controlled clinical trial was conducted.” PMID 29238974 ↗ Dec 20171“Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in China.” PMID 23693018 ↗ May 2013 |
| Action | Inhibit | “Endostatin is a multiple targeted angiogenesis inhibitor” NCT02590133 ↗ |
| Modality | Protein / enzyme biologic | “Human Recombinant Endostatin” NCT00004229 ↗ |
| Route | Intravenous | “Patients receive endostatin IV daily for 4 weeks.” NCT00004229 ↗ |